

Brief update on the MCM project and the team – November 2017.

The *Mapping Cancer Markers* (MCM) project continues to process work units for the Ovarian Cancer dataset. We are also in the process of analyzing MCM results from the Lung Cancer dataset, and we are finalizing preparation of the new work units for the sarcoma project. We will devote more space in the next project update to this work. Below we provide details about the exciting new development in the team.

[The Move](#)

After 17+ years at Ontario Cancer Institute (now Princess Margaret Cancer Centre) we got an opportunity to join Krebil Research Institute (KRI) to work on a more complex approach to chronic diseases, where we have moved last week. KRI is still part of UHN, but focuses also on arthritis, neuroscience and vision. The research and translational clinical research interests focus not only on diagnosis and improved treatment but importantly on prevention, which aligns with my group's interest over the last few years.

Thus, MCM has not been negatively affected – the physical move was smooth, and our servers stayed in the original server rooms, reducing the risk of any hiccup for the work-units and results. We will not only continue but expand on our research.

Importantly, we are in the finalizing stages of paperwork to embark on a newly-funded research by the Ontario Government: *The Next Generation Signalling Biology Platform*. This will provide us funds to create a software infrastructure for the comprehensive, integrative computational biology analyses workflows, in collaboration with translational research and clinical trials groups. Our partners are Princess Margaret Cancer Centre, Krebil Research Institute, University of Toronto, University of Montreal, BC Cancer Agency, Cancer Clinical Trials Group, Queen's University and European Bioinformatics Institute (IMEx Consortium). Besides cancer focus, this is also our first large project on osteo-arthritis research.

Sincerely

Igor Jurisica
for the MCM team